Beneficial Antipsychotic Effects of Celecoxib Add – on Therapy Compared to Clozapine Alone in Schizophrenia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201301095280N11

Enrollment

Registered

2013-02-16

Start date

2005-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: clozapine plus 100 mg/day celecoxib, towice a day, One month. Intervention 2: Control group: clozapine plus placebo.

Treatment - Drugs

Placebo

Intervention group: clozapine plus 100 mg/day celecoxib, towice a day, One month.

Control group: clozapine plus placebo.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis of schizophrenia based on DSM-IV criteria; not using long acting antipsychotics since the last month; not using any oral antipsychotic except clozapine since the last week. Exclusion criteria: any side effects of drugs; need to changing antipsychotic drugs or adding new one.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Schizophrenia. Timepoint: Baseline, 2nd, 4th weeks. Method of measurement: PANSS test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Roya Samadi

Mashhad University of Medical Sciences

samadir881@mums.ac.ir+98 51 1711 2721

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026